The Manufacturers Life Insurance Company Makes New $125.54 Million Investment in Zimmer Biomet Holdings, Inc. $ZBH

The Manufacturers Life Insurance Company bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,458,259 shares of the medical equipment provider’s stock, valued at approximately $125,542,000. The Manufacturers Life Insurance Company owned about 0.76% of Zimmer Biomet as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $204,000. Sivia Capital Partners LLC acquired a new position in Zimmer Biomet in the second quarter worth about $232,000. United Bank increased its holdings in shares of Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after acquiring an additional 1,153 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Zimmer Biomet by 129.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after acquiring an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC lifted its stake in Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock worth $7,004,000 after purchasing an additional 37,116 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group raised their price target on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. BMO Capital Markets reissued a “market perform” rating and issued a $96.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Robert W. Baird set a $104.00 price target on Zimmer Biomet in a research report on Thursday, August 6th. UBS Group restated a “buy” rating and set a $120.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Wells Fargo & Company dropped their target price on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $104.42.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is owned by corporate insiders.

Zimmer Biomet Trading Down 0.7%

Shares of ZBH stock opened at $100.25 on Wednesday. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The firm has a market capitalization of $19.12 billion, a PE ratio of 24.39, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45. The stock has a fifty day moving average of $93.11 and a two-hundred day moving average of $91.22. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.